 |
Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes.
|
Press Release
June 10, 2009
Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009 ... read more »
Oramed Presents Poster at ADA in New Orleans
June 8, 2009
Open- Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin Formulation in Subjects with type 2 Diabetes (T2DM) ... read more »
|